Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
MAB.WA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.22
-59%
0.97
vs 2.39
Q1.23
+122%
1.02
vs 0.46
Q2.23
+195%
0.94
vs 0.32
Q3.23
+435%
0.67
vs -0.20
Q4.23
N/A
-0.08
vs 0.97
Q1.24
+7%
1.09
vs 1.02
Q2.24
-32%
0.64
vs 0.94
Q3.24
N/A
-1.01
vs 0.67
Q4.24
N/A
-1.11
vs -0.08
Q1.25
N/A
-0.94
vs 1.09
Sales Growth
YoY
Current
Estimates
Q4.22
-22%
42.9M vs 55.3M
Q1.23
+2%
39.5M vs 38.6M
Q2.23
-18%
36M vs 43.9M
Q3.23
-23%
29.6M vs 38.5M
Q4.23
+8%
46.5M vs 42.9M
Q1.24
-14%
34M vs 39.5M
Q2.24
-17%
29.8M vs 36M
Q3.24
-98%
516K vs 29.6M
Q4.24
-90%
4.8M vs 46.5M
Q1.25
-92%
2.7M vs 34M
Return on Equity
QoQ
Q2.23
+14%
0.14
vs 0.18
Q3.23
+9%
0.09
vs 0.14
Q4.23
-1%
-0.01
vs 0.09
Q1.24
+13%
0.13
vs -0.01
Q2.24
+7%
0.07
vs 0.13
Q3.24
-13%
-0.13
vs 0.07
Q4.24
-16%
-0.16
vs -0.13
Q1.25
-16%
-0.16
vs -0.16
Institutionnal Ownership
Relative Strength
MAB.WA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Forecast
2109%2026-Revenue
62%2026-EPS
265%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.
WSE
Unprofitable
Unprofitable
-0.20 ( -2.00%)
Relative Strenght
Volume Buzz
-19%
Earning Acce
No
Dist 52w H.
52%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How MAB.WA compares to sector?